Literature DB >> 10982113

Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women.

B J Turner1, C J Newschaffer, D Zhang, L Cosler, W W Hauck.   

Abstract

BACKGROUND: Antiretroviral treatment for HIV-infected women is standard during pregnancy to prevent vertical transmission, but data on postpartum therapy for the mother are lacking.
OBJECTIVE: The objective of this study was to examine the impact of provider and patient characteristics on receipt of antiretroviral therapy and pharmacy-based measurement of adherence by postpartum HIV-infected women. RESEARCH
DESIGN: This was a retrospective cohort study.
SUBJECTS: The study included 2,648 New York State Medicaid-enrolled HIV-infected women who delivered from January 1993 through October 1996 and were followed up through September 1997. MEASURES: From Medicaid claims in the first postpartum year, the study examined any prescribed antiretroviral therapy and, among women treated >2 months, adherence, defined as > or =80% days covered by prescribed therapy from first to last antiretroviral prescription.
RESULTS: Antiretroviral therapy was prescribed for 681 (26%) study women. Of 292 women treated >2 months, 28% were adherent on the basis of the pharmacy-based measure. The proportion of treated women was highest in 1996 (40%), and adherence was best in 1995 (44%) when most women took monotherapy. The adjusted odds ratios (AORs) of treatment were 1.67 (95% CI, 1.24 to 2.25) for women receiving HIV-focused services and 2.71 (95% CI, 1.99 to 3.69) for women with a provider in an HIV-related specialty. The AORs of adherence were greater for women with HIV-focused services (2.13; 95% CI, 1.05 to 4.30) and for former illicit drug users versus nonusers (2.40; 95% CI, 1.05 to 5.50).
CONCLUSIONS: This population-based pharmacy analysis reveals improving antiretroviral use but continuing poor pharmacy-based adherence by postpartum HIV-infected women. Receipt of HIV-focused services appears to be particularly beneficial in increasing the likelihood of treatment and adherence.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10982113     DOI: 10.1097/00005650-200009000-00005

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  26 in total

1.  Daily regimen and compliance with treatment.

Authors:  B S Bloom
Journal:  BMJ       Date:  2001-09-22

2.  Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users.

Authors:  Julia H Arnsten; Penelope A Demas; Richard W Grant; Marc N Gourevitch; Homayoon Farzadegan; Andrea A Howard; Ellie E Schoenbaum
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

3.  A 2-arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART.

Authors:  Carol E Golin; Joanne Earp; Hsiao-Chuan Tien; Paul Stewart; Carol Porter; Lynn Howie
Journal:  J Acquir Immune Defic Syndr       Date:  2006-05       Impact factor: 3.731

4.  Research results have expiration dates: ensuring timely systematic reviews.

Authors:  Julie Barroso; Margarete Sandelowski; Corrine I Voils
Journal:  J Eval Clin Pract       Date:  2006-08       Impact factor: 2.431

Review 5.  In or out? Methodological considerations for including and excluding findings from a meta-analysis of predictors of antiretroviral adherence in HIV-positive women.

Authors:  Corrine I Voils; Julie Barroso; Victor Hasselblad; Margarete Sandelowski
Journal:  J Adv Nurs       Date:  2007-06-03       Impact factor: 3.187

Review 6.  Use of pharmacy refill data as a measure of antiretroviral adherence.

Authors:  Robert Grossberg; Robert Gross
Journal:  Curr HIV/AIDS Rep       Date:  2007-12       Impact factor: 5.071

7.  Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227.

Authors:  Mary A Vogler; Laura M Smeaton; Rodney L Wright; Sandra W Cardoso; Jorge Sanchez; Rosa Infante; Laura E Moran; Catherine Godfrey; Lisa M Demeter; Victoria A Johnson
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-15       Impact factor: 3.731

8.  Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram.

Authors:  Eric Q Wu; Paul E Greenberg; Rym Ben-Hamadi; Andrew P Yu; Elaine H Yang; M Haim Erder
Journal:  Am Health Drug Benefits       Date:  2011-03

9.  The cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women.

Authors:  Caitlin J McCabe; Sue J Goldie; David N Fisman
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

Review 10.  ART uptake and adherence among women who use drugs globally: A scoping review.

Authors:  Jennifer L Glick; Aimee Huang; Rienna Russo; Belinda Jivapong; Vijayasundaram Ramasamy; Lori Rosman; Danielle Pelaez; Katherine H A Footer; Susan G Sherman
Journal:  Drug Alcohol Depend       Date:  2020-08-02       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.